<DOC>
	<DOCNO>NCT02216331</DOCNO>
	<brief_summary>This open-label study , 2-treatment , 2-period , single sequence design . Period 1 examine pharmacokinetics TMC207 absence rifapentine rifampicin . Subjects receive single 400-mg dose TMC207 administer alone Study Day 1 . Period 2 examine effect repeat dos either rifapentine rifampicin TMC207 pharmacokinetics begin Study Day 20 . During Period 2 , subject receive 22 daily dos either 600 mg rifapentine rifampicin Study Day 20 Study Day 41 . A single 400-mg dose TMC207 administer Study Day 29 . Subjects confine clinic Study Day-1 Study Day 2 morning Period 1 , Study Day 19 Study Day 30 morning Period 2 . The study hypothesis determine whether Rifapentine affect pharmacokinetics TMC207 measure effect Cmax AUC ( 0-t ) less degree rifampicin .</brief_summary>
	<brief_title>PK Interaction Between Rifapentine Rifampicin Single Dose TMC207 Healthy Subjects ( TMC207-CL002 )</brief_title>
	<detailed_description />
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Rifapentine</mesh_term>
	<mesh_term>Bedaquiline</mesh_term>
	<mesh_term>Diarylquinolines</mesh_term>
	<criteria>Aged 19 55 year , extremes include . Non tobacco/nicotine use ( least 3 month prior screen ) . Body Mass Index ( BMI , weight kg divide square height meter ) 18.0 32.0 kg/m2 , inclusive . Informed Consent Form ( ICF ) sign voluntarily first trialrelated activity . Able comply protocol requirement . Healthy basis medical evaluation history reveals absence clinically relevant abnormality include physical examination , medical history , electrocardiogram ( ECG ) , vital sign , result blood biochemistry , hematology test urinalysis carry screening ( See Section 6.1 ) . Female , except postmenopausal since 2 year , posthysterectomy , post surgical sterilization , i.e. , tubal ligation ( without reversal operation ) total hysterectomy . History evidence current use alcohol , barbiturate , amphetamine , recreational narcotic drug use , investigator 's opinion would compromise subject 's safety and/or compliance trial procedure . Any clinically significant ( deemed Principle Investigator ) history acute illness ( resolve within 4 week screen ) , presence cardiovascular , pulmonary , hepatic , renal , hematologic , gastrointestinal ( include eat disorder ) , endocrine , metabolic , immunologic , dermatologic , neurologic , psychological , psychiatric disease . Currently significant diarrhea , gastric stasis , constipation investigator 's opinion could influence drug absorption bioavailability . Any history significant skin disease , limited , rash eruption , drug allergy , food allergy , dermatitis , eczema , psoriasis , urticaria . Subjects history skin disease may enrol study consultation Sponsor Medical Monitor . Previously demonstrate clinically significant allergy hypersensitivity excipients investigational medication administer trial ( i.e . rifapentine , rifampicin , TMC207 ) . Subjects QTcF [ Fredericia correction ] interval &gt; 450 msec ( base average triplicate ECGs ) screening ( confirm repeat ECG ) . Subjects clinically significant ECG abnormality screening , arrhythmia , ischemia , evidence heart failure family history Long QT Syndrome . Use concomitant medication , include overthecounter product dietary supplement , except ibuprofen paracetamol 7 day first dose trial medication prescribe medication must discontinue least 14 day first intake trial medication . Participation investigational drug trial within 60 day prior first intake trial medication . Donation blood significant loss blood within 56 day plasma donation within 7 day precede first intake trial medication . Having receive TMC207 previous trial . Positive HIV1 HIV2 test screen Hepatitis A , B , C infection ( confirm hepatitis A antibody IgM , hepatitis B surface antigen , hepatitis C virus antibody , respectively ) screening . A positive urine drug test screening . Urine test check current use alcohol , amphetamine , benzodiazepine , cocaine , cannabinoids , opioids . Subjects follow laboratory abnormality screen defined NIH , NIAID , Division Microbiology Infectious Diseases ( DMID ) Adult Toxicity Table accordance normal range clinical laboratory : Serum creatinine grade 1 great ( &gt; 1.0 x ULN ) ; Pancreatic lipase grade 1 great ( &gt; 1.0 x ULN ) ; Hemoglobin grade 1 great ( ≤ 10.5 g/dL ) ; Platelet count grade 1 great ( ≤ 99000/mm3 ) ; Absolute neutrophil count grade 1 great ( ≤ 1500/mm3 ) ; Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) grade 1 great ( &gt; 1.0 x ULN ) ; Total bilirubin grade 1 great ( &gt; 1.0 x ULN ) ; Any toxicity grade 2 , include : proteinuria ( spot urine ) &gt; 1+ gross hematuria .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>tuberculosis</keyword>
	<keyword>PK</keyword>
	<keyword>TMC207</keyword>
	<keyword>bedaquiline</keyword>
	<keyword>rifapentine</keyword>
	<keyword>rifampicin</keyword>
	<keyword>drug drug interaction</keyword>
</DOC>